Form 4: Arvinas Inc. Executive Angela M. Cacace Reports Stock and Option Awards

Angela M. Cacace, Chief Scientific Officer of Arvinas Inc., reports the acquisition of restricted stock units and stock options, signaling changes in her beneficial ownership of the company's securities.

Summary

• On June 17, 2024, Angela M. Cacace, the Chief Scientific Officer of Arvinas Inc., was granted 15,995 restricted stock units (RSUs) and an option to purchase 24,632 shares of Arvinas' common stock.
• The RSUs and options were granted pursuant to Arvinas' 2018 Stock Incentive Plan.
• The RSUs represent a contingent right to receive one share of Arvinas' common stock upon settlement for no consideration.
• Both the RSUs and the options vest over two years, with 1/2 vesting on June 17, 2025, and the remainder on June 17, 2026.
• Following these transactions, Cacace directly owns 51,852 shares of Arvinas' common stock and holds options for 24,632 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity to a key executive is generally a positive sign, indicating alignment of interests. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The grant of RSUs and stock options to a key executive like the Chief Scientific Officer can be seen as a positive sign, aligning her interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

This type of equity compensation is common in the biotechnology industry to incentivize and retain key executives, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation packages, including stock options and RSUs, are a standard practice in the biotech industry to attract and retain top talent.
• Companies like Amgen, Gilead, and Biogen routinely grant similar equity awards to their executives.
• The vesting schedules, typically ranging from two to four years, are also in line with industry norms.

Stakeholder Impact

• Shareholders may view the equity grants as a way to incentivize management and align their interests with the company's long-term performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates